Introduction
The proto-oncogene c-myc encodes a bHLHZip transcription factor implicated in the control of cell growth. Deregulated expression of c-Myc, as well as other members of the Myc protein family, is frequently observed in human cancer (Cole, 1986; Kelly and Siebenlist, 1986; Spencer and Groudine, 1991) . The bHLHZip domain of c-Myc mediates heterodimerization with its partner protein Max (Blackwood and Eisenman, 1991) , which is required for sequence speci®c DNA binding (Blackwell et al., 1990) to its E box recognition site and concomitant transcriptional activation (Amati et al., 1992) . Max also heterodimerizes with members of the Mad protein family, Mad1 (Ayer et al., 1993) , Mxi (Zervos et al., 1993) , Mad3 and Mad4 (Hurlin et al., 1995) . Mad/Max complexes are thought to bind the same E box motif as Myc/Max complexes but act as transcriptional repressors (Ayer et al., 1993) . Myc, Max and Mad proteins therefore comprise a network in which Myc and Mad proteins compete for Max (Amati and Land, 1994) .
c-Myc is implicated in a variety of cellular processes. It has a well-characterized role in inducing and/or promoting cell proliferation. In normal cells, its expression is tightly dependent upon mitogen stimulation and, at least in certain cell types, its expression is sucient to induce cell cycle entry (Eilers et al., 1991) . Moreover, inhibition of c-myc expression prevents entry of quiescent lymphocytes into S phase and triggers growth arrest in proliferating hematopoietic cells (Heikkila et al., 1987) . Under conditions of survival factor deprivation, however, c-Myc is also a potent inducer of apoptosis Askew et al., 1991) . Thus, although ®broblasts with deregulated c-myc expression continue to cycle in the absence of serum, they eventually undergo apoptosis unless provided with survival factors such as IGF-I (Harrington et al., 1994) or anti-apoptotic proteins such as Bcl-2 (Bissonnette et al., 1992; Fanidi et al., 1992; Wagner et al., 1993) . The molecular mechanism by which cMyc induces apoptosis is unknown, although sitedirected mutagenesis studies indicate that the same regions of c-myc required for sequence-speci®c transcriptional activation are also required to promote proliferation and to trigger apoptosis, suggesting that both proliferation and apoptosis are mediated through transcriptional modulation of target genes Amati et al., 1993) . Recently, it has become clear that c-Myc sensitizes cells to a wide range of proapoptotic stimuli, such as activation of the Fas (Hueber et al., 1997) and TNF (Klefstrom et al., 1994) pathways, hypoxia (Alarcon et al., 1996) or DNA damage , by triggering release of cytochrome c from mitochondria into the cytosol (Juin et al., 1999) .
During T cell development, thymocytes dierentiate and mature within the thymus through an ordered series of proliferation and maturation events, each characterized by speci®c pattern of expression of the CD4 and CD8 co-receptors. The most immature thymocytes are CD4 7 CD8 7 (DN), which then mature through a CD4 + CD8 + double positive (DP) stage, ending as either mature CD8 7 CD4 + or CD8 + CD4 7 single positive (SP) T cells. Only those thymocytes bearing functional T cell receptors with appropriate speci®cities are positively selected and dierentiate fully (Marrack et al., 1993) . The remaining ones undergo negative selection and die by apoptosis (Tough and Sprent, 1994; Shortman et al., 1990) . Since proliferation, dierentiation and apoptosis play such crucial roles in T cell development, the thymus presents itself as a particularly informative experimental system in which to analyse the consequences of c-Myc activation in vivo. To date, conventional transgenic technology has been used to target c-myc expression to lymphocytes (CD2-c-myc, Thy1-c-myc, Em-c-myc) (Stewart et al., 1993; Spanopoulou et al., 1989; Adams et al., 1985) . However, all these studies suer from the limitation of classical transgenic technology in that the transgene in question is placed under the control of a tissue-speci®c regulatory element that is typically expressed throughout the ontogeny of an organ or tissue. This makes it impossible to examine the immediate and short-term consequences of c-Myc activation. Moreover, sustained expression of c-myc in lymphocytes induces lymphomas, which complicates analysis of any of the longterm consequences of c-myc expression other than neoplasia. Attempts at deducing c-myc function using gene knockout strategies are precluded by the early embryonic lethality of c-myc knockout mice, which typically die between day 9.5 and 10.5 of gestation, long before the onset of lymphocyte ontogeny (Davis et al., 1993) .
Our approach to study the consequences of c-myc expression for lymphocytes in vivo has been to transgenically target expression of a switchable form of the c-Myc protein to thymocytes and peripheral T cells using the proximal lck promoter. This conditional c-Myc protein is a chimera of c-myc fused to the modi®ed ligand-binding domain of the mouse estrogen receptor (c-MycER TM ). The resulting c-MycER TM protein is functionally active only in the presence of the synthetic steroid 4-hydroxytamoxifen (4-OHT), but refractory to b-17-estradiol (Littlewood et al., 1995) . We demonstrate that whilst activation of c-Myc has no obvious eect on thymocyte ontogeny, more discriminating analysis indicates that c-myc expression perturbs positive selection. The eect on positive selection appears principally due to a facilitation of thymocyte proliferation. Consistent with this, splenic T cells from lck-c-mycER TM transgenic mice in which c-MycER TM has been activated in vivo display enhanced proliferation when mitogenically stimulated with anti-CD3/ CD28 antibody in vitro. Activation of c-MycER TM also promotes apoptosis in thymocytes in vitro.
Results

Generation of lck-c-mycER
TM transgenic mice
We targeted expression of the 4-OHT-dependent cMycER TM protein to thymocytes and mature peripheral T lymphocytes using the proximal lck promoter (Wildin et al., 1991) . Figure 1a shows a schematic representation of the lck-c-mycER TM expression construct, which includes a 3.2 kb fragment of the proximal lck promoter, a 2.3 kb human c-mycER TM cDNA (Littlewood et al., 1995) and 2.1 kb of genomic sequence derived from the human growth hormone gene (hgh). A 7.6 kb BamHI fragment was injected into C57BL/6/CBA F1 embryos using standard techniques . Two founder lines were generated, both of which harbour roughly the same copy number (*10 copies, data not shown), behaved identical, and are therefore not further distinguished during analysis presented.
Expression of the c-mycER TM transgene was assayed by Northern blot analysis of total RNA using a human c-myc cDNA probe. Expression of the transgene was detected in transgenic thymus tissue and, to a weaker extent, in transgenic spleen tissue. No expression was detected in thymus or spleen of control littermates (data not shown). In addition, Western immunoblot analysis using an antibody (9E10) speci®c for the human c-Myc protein (Evan et al., 1985) revealed the Figure 1 Generation of lck-c-mycER TM transgenic mice. (a) Schematic representation of the lck-c-mycER TM transgenic construct. The human c-myc cDNA fused to the ligand-binding domain of the murine estrogen receptor was cloned into the BamHI cloning site under the control of the thymocyte speci®c proximal lck promoter using the p1017 expression vector (Chan et al., 1990) . Two independent transgenic founder lines were generated. (b) Western immunoblot analysis shows expression of the lck-c-mycER TM transgene in thymus and spleen. Protein lysates from the indicated tissues were separated on a 7.5% denaturing polyacrylamide gel, transferred to a PVDF membrane and probed with an anti-c-myc antibody, speci®c for the human c-Myc protein (9E10) (Evan et al., 1985) . A lysate from Swiss 3T3 MycER TM cell line (Littlewood et al., 1995) was used as a positive control. The protein expression of the 97 kDa MycER TM protein is indicated with an arrow (Figure 1b) . As observed for many other transgenes driven by the proximal lck promoter (Calan et al., 1995; Miyazaki and Lemmonier, 1998) Activation of c-MycER TM by 4-hydroxytamoxifen has previously been demonstrated in rodent ®broblast in vitro in which both c-Myc-dependent proliferation and apoptosis are dependent upon the presence of 4-OHT (Littlewood et al., 1995) . Recently we demonstrated the utility of the c-MycER TM system for the reversible regulation of c-Myc action in vivo. Using the involucrin promoter to drive expression of c-MycER TM we were able to reversibly activate c-Myc in suprabasal keratinocytes by topical application of 4-OHT (Pelengaris et al., 1999) . This resulted in c-Myc-dependent induction of keratinocyte proliferation together with a block in keratinocyte dierentiation, resulting in hyperplasia and angiogenesis, ultimately generating cMyc-dependent papillomatosis (Pelengaris et al., 1999) . Because the thymus is an internal organ, in the case of lck-targeted c-MycER TM we choose to activate cMycER TM by intraperitoneal administration of 4-OHT in peanut oil.
To test for any side eects of 4-OHT on thymocytes, we administered either peanut oil carrier alone or peanut oil with 4-OHT to wild-type control mice and analysed their thymocyte pro®les. Peanut oil alone had no discernible eect on T cell development. Similarly, daily administration of doses of 4-OHT up to 2 mg/ animal also had no visible eect on T cell ontogeny, even when administered long term for up to 3 weeks (data not shown). However, short-term injections of very high doses of 4-OHT (four daily injections with 3 or 5 mg 4-OHT/injection) caused clear changes in wildtype control mice, as evidenced by dramatic reduction in thymic cellularity and distortion of T cell development. In response to very high doses the ratio of the DP sub population was reduced compared to uninjected or oil injected control littermates (data not shown). Accordingly, we activated c-MycER TM using daily doses of 2 mg 4-OHT/animal/day. In all experiments, controls comprised lck-c-mycER TM transgenic animals treated with peanut oil carrier alone, nontransgenic littermates treated with 4-OHT and, in addition, a further control littermate was always treated with peanut oil on its own.
Activation of the lck-c-MycER
TM protein in an H-Y-TCR background perturbs thymic selection
To investigate any eect that c-Myc activation might exert on T cell development in vivo, lck-c-mycER TM transgenic mice (4 ± 10 weeks old) were treated with 4-OHT for 9 ± 12 days. 24 h after the last IP injection of 4-OHT mice were sacri®ced and their thymocytes analysed by three-colour¯ow cytometry using antibodies against markers for CD25, CD3e, CD69, TCRa (data not shown) in combination with CD4 and CD8 to discriminate between the dierent thymocyte sub populations. Perhaps surprisingly, given c-Myc's potent mitogenic and pro-apoptotic potential in many cell types, activation of c-MycER TM with 4-OHT caused no evident change to the ratios of the four thymocyte sub population in the adult (Figure 2a ). The level of all cell surface markers tested was unchanged and no signi®cant eect was observed on thymic cellularity when lck-c-mycER TM transgenic mice were compared to control littermates ( Figure 2b ).
Many experimental perturbations of T cell signal or survival pathways have been reported to have little eect on gross¯ow cytometric pro®les of T cell ontogeny. T cell development and cellularity appear to be robust processes under stringent homeostatic control. A more discriminating system with which to examine more subtle eects on T cell development is the well-characterized H-Y-TCR model system for looking at positive and negative T cell selection Teh et al., 1989; von Boehmer, 1990) . This system uses mice expressing a transgenic T cell receptor speci®c for the male H-Y-antigen presented by MHC class I H-2D b . In male mice almost all thymocytes are negatively selected during T cell development because of interaction between the transgenic H-Y-TCR and the widely expressed endogenous male-speci®c H-Y peptide. In female mice, where no male H-Y-antigen is present, selection of MHC class I restricted CD8 + SP thymocytes proceeds very eciently. Therefore thymocytes expressing the H-Y-speci®c transgenic TCR are positively selected.
First, a comparison of thymuses from female lck-cmycER TM 6H-Y-TCR double transgenic mice with thymuses from control H-Y-TCR transgenic mice showed a dierence in thymic cellularity: a signi®cant increase in thymic cellularity was observed in female lck-c-mycER TM 6H-Y-TCR double transgenic mice compared to control littermates (Figure 3a, table) . Second, three-colour¯ow cytometry using antibodies for the T cell speci®c markers CD4, CD8, plus an antibody speci®c for the transgenic H-Y-TCR (T3. + cells in peripheral lymph nodes (data not shown). Therefore the only thing to conclude from these data is that c-Myc activation does not seem to enhance negative selection.
TM protein induces proliferation in vitro and in vivo Because it has been published that c-Myc has a dual role as inducer of proliferation and apoptosis , we investigated the consequences of c-Myc activation in lck-c-mycER TM thymocytes in vitro. In the absence of mitogenic activation, explanted thymocytes are quiescent (G0) in vitro. Stimulation by mitogens induces cell cycle entry and proliferation and is accompanied by rapid induction of endogenous c-myc (Carding and Reem, 1987) . C-myc appears necessary for thymocyte proliferation since inhibition of c-myc expression using antisense oligonucleotides blocks entry of T lymphocytes into cycle (Heikkila et al., 1987) . First, to test the importance of c-myc activation for T lymphocyte proliferation in vitro, puri®ed T cells derived from either lck-c-mycER TM transgenic mice or control littermates treated with 4-OHT were mitogenically stimulated with anti-CD3/CD28 antibodies for 72 h in the presence of 4-OHT in the culture medium (Figure 4a,b) . To monitor proliferation over time, puri®ed T cells were labeled before plating in vitro with carboxy¯uorescein succinimidyl ester (CFSE), a stablē uorescent dye that binds irreversibly to the cell surface and segregates equally between daughter cells upon cell division (Wells, 1997) . Thus, as T cells divide their¯uorescence halves sequentially with each generation. When analysed by¯ow cytometry, gating on the living cells by forward/side scatter, showed that unstimulated splenic T cells from either lck-c-mycER TM transgenic mice (MycER TM ) were injected daily with 4-OHT (2 mg/IP) for 9 days and were then left untreated for another 7 days. Then 1610 6 CFSE stained, puri®ed T cells from these mice were either left untreated or plated in the presence of immobilized anti-CD3/CD28 antibody for 72 h and FACS analysis was performed. Representative CFSE FACS pro®les from non-stimulated T cells (thick line) and pro®les from anti-CD3/CD28 co-stimulated T cells (thin line) from wild-type control littermates (wt) and lck-c-mycER TM transgenic mice (MycER TM ) are shown. The dierent peaks visible in response to anti-CD3/CD28 treatment represent successive cell divisions. Each peak represents a cell population that has divided a certain number of times. The relative size of each peak is shown as a percentage of alive cells on the right hand side of the ®gure. Shown is the result of a representative experiment transgenic mice or control littermates exhibited a sharp single peak indicating no cell division. Thus a c-Myc activation alone is not sucient to cause G0 ± G1 progression. In contrast,¯ow cytometric analysis of mitogenically treated control T cells revealed an increase in the forward/side scatter indicating activation of the T cells and the presence of multiple distinct peaks representing successive cell divisions (Figure 4a and data not shown). Marked asynchrony in numbers of divisions was observed, with some T cells having divided as many as ®ve times (peak 6) after 72 h of costimulation while others remained undivided throughout the same period (peak 1). When compared with mitogenically stimulated thymocytes from wild-type control littermates, mitogenic stimulation of T cells derived from lck-c-mycER TM transgenic mice led to less cells unresponsive to anti-CD3/CD28 stimulation. Whereas 24.9% of alive splenic T cells derived from control mice are refractory to mitogenic stimulation, only 14.4% of alive lck-c-mycER TM T cells remain undivided (Figure 4b ). Thus, after anti-CD3/CD28 costimulation the initial G0 ± G1 entry into the cell cycle seems clearly increased in lck-c-mycER TM transgenic mice when compared to T cells from wild-type control littermates, indicating an enhanced proliferative response (Figure 4a,b) . The enhanced proliferative phenotype caused by c-MycER TM activation is reversible. T cells derived from mice left 7 days since their last 4-OHT injection showed identical proliferative pro®les to T cells derived from control littermate mice (Figure 4c,d) .
Second, we examined the eect of c-Myc activation on the proliferative potential of thymocytes in vivo using our H-Y-TCR positive selection model. 4-OHT was administered daily by IP injection for 9 days to either female H-Y-TCR control littermates or female lck-c-mycER TM 6H-Y-TCR double transgenic mice to activate c-MycER TM . Mice were then given two IP injections of BrdU half an hour apart and 6 h after the second injection their thymocytes removed and assayed for proliferative status by¯ow cytometry. As shown in Figure 5 , female lck-c-mycER TM 6H-Y-TCR double transgenic mice exhibit an increase in the number of proliferating, BrdU positive thymocytes when compared with their H-Y-TCR control littermates. This eect is most profound in CD8 + SP cells that show a 17-fold increase in the proportion of proliferating cells (Figure 5 ). An increase in the percentage of BrdUpositive thymocytes was also observed in male lck-cmycER TM
6H-Y-TCR double transgenic mice when compared with their H-Y-TCR control littermates (data not shown). Thus activation of the lck-cmycER TM transgene in an H-Y-TCR background enhances proliferation in vivo.
Activation of the lck-c-mycER TM transgene induces apoptosis in vitro To investigate any eect that c-Myc activation might have on apoptosis, thymocytes from either lck-cmycER TM transgenic mice or control littermates were isolated and cultured in DMER medium supplemented with 10% FCS in the presence or absence of 200 nM 4-OHT. After 18 ± 22 h in culture, the extent of apoptosis in culture was assessed by Annexin V staining. There was no signi®cant dierence in the amount of apoptosis between non-treated lck-c-mycER TM and non-or 4-OHT treated thymocytes from wild-type control littermates. The background rate of apoptosis was about 20% after 18 ± 22 h in culture. This was consistent in dierent independent experiments. Therefore, addition of 4-OHT to the culture medium of nontransgenic thymocytes had no eect on the normal death rate in culture. Activation of c-Myc however led to a signi®cant increase in apoptosis of about 20% above background death in thymocytes isolated from lck-c-mycER TMt transgenic mice. Again the amount of apoptosis induced by c-Myc activation was very consistent in dierent independent experiments. Thus, the increase in apoptosis above background was dependent on the presence of both 4-OHT and the cMycER TM protein ( Figure 6 ). In addition, Myc-induced apoptosis in thymocytes was clearly blockable by adding 25 mM Z-VAD-FMK to the culture medium showing caspase-dependency (data not shown).
We also examined the eect of Myc activation on apoptosis in vivo using TUNEL assay. Frozen thymus sections from wild-type control littermates, lck-cmycER TM transgenic mice, female H-Y-TCR control littermates and female lck-c-mycER TM 6H-Y-TCR double transgenic mice injected with 4-OHT were stained. Dierent microscopic ®elds were examined for each tissue section. Apoptosis was easily detectable, however no signi®cant, reproducible dierence in the 6H-Y-TCR double transgenic mice were compared (data not shown). In addition, thymocytes from control littermates and lck-c-myc ER TM transgenic mice were isolated and immediately after isolation (ex vivo) the amount of apoptosis was estimated by Annexin V staining. Using this technique the amount of apoptosis detectable was very low (*3 ± 6% of all cells were apoptotic) and no signi®cant, reproducible dierences in apoptosis were observed comparing wild-type control littermates and lck-c-mycER TM transgenic mice, probably because of the extremely rapid removal of apoptotic cells by macrophages in vivo (Surh and Sprent, 1994) (data not shown).
Discussion
So far using conventional transgenic mouse technology dierent c-myc transgenic mice have been generated by targeting expression of the c-myc transgene to the lymphoid compartment (CD2-c-myc,Thy1-c-myc, Em-cmyc) (Stewart et al., 1993; Spanopoulou et al., 1989; Adams et al., 1985) . However, classical transgenic technology suers from the limitation that the transgene in question is placed under the control of a tissue-speci®c regulatory element that is normally expressed throughout the ontogeny of an organism. In the case of all transgenic mice where c-myc is expressed in the lymphoid compartment, constitutive deregulated c-myc expression resulted in the formation of tumours which made it dicult to analyse these mice. Tumours are of a clonal nature, arising rapidly after birth (Stewart et al., 1993; Adams et al., 1985; Spanopoulou et al., 1989) .
In this study, we demonstrate that it is possible to regulate c-Myc activity in the lymphoid compartment thus allowing the analysis of c-myc function in the thymus without spontaneous tumour development. We have generated transgenic mice in which the expression of a switchable c-Myc protein was targeted to the thymus (lck-c-mycER TM ). To make the activity of the cMyc protein switchable, the c-myc cDNA was fused to the modi®ed ligand-binding domain of the murine estrogen receptor. Activation of the c-MycER TM protein in vivo was achieved by intraperitoneal injection of the synthetic estrogen analogue 4-hydroxytamoxifen (4-OHT). A recent report from our laboratory demonstrates the successful use of such a regulatable MycER TM system in the skin. In these experiments 4-OHT was applied by direct topical application to the skin (Pelengaris et al., 1999) . Though this method is very powerful, it can not be universally used for internal organs, and has therefore clear limitations.
Here we have shown that intraperitoneal injections of 4-OHT can activate the MycER TM protein in internal tissues.
The use of such a regulatable protein expressed under the control of a tissue speci®c promoter provides new opportunities for the analysis of protein function in the context of both the developing and adult animal. In the case of MycER TM , the transgene is expressed continuously, its activity however can be tightly regulated by administration of the estrogen analogue 4-OHT. In addition cessation of 4-OHT treatment and consequent deactivation of MycER TM allows analysis of the reversibility of the in vivo eects of c-Myc (Pelengaris et al., 1999; and this paper) . Taking into account that long-term studies of 4-OHT demonstrated a very low toxicity (Furr et al., 1979; Watanabe et al., 1980) this clearly opens new opportunities for the analysis of protein function in vivo.
In the study presented here, we found that transgenic mice constitutively expressing a switchable c-MycER TM protein under the control of the T cell speci®c proximal lck promoter either in the presence or absence of 4-OHT display T cell development with no obvious eect on the representation of various thymocyte sub populations in the adult mice. c-Myc activation in lck-c-mycER TM transgenic mice therefore does not lead to substantial alterations in the proportion of cells in dierent T cell sub populations. This observation is in contrast to a previous report, which described a larger proportion of thymocytes with high TCR/CD3 high and HSA-1 low expression and an increase in the CD4 + CD8 low transitional population in Eb-myc transgenic mice (Broussard-Diehl et al., 1996) . Broussard-Diehl et al. (1996) suggested that the increase in proportion of the CD4 + CD8 low population in the Eb-myc transgenic might be due to an increase in the number of cells passing through the initial stage of positive selection. However, a simple decrease in the CD4 + CD8 low transit time or a block in the CD4 + CD8 low to CD4 + SP transition would be thinkable as well. The dierence observed between both transgenic mice might be due to the use of a dierent promoter and/or due to the fact that in lck-c-mycER TM transgenic mice in contrast to the Eb-myc mice the transgene is not permanently active but only activated in the adult by 4-OHT administration. A more detailed analysis using the H-Y-TCR T cell selection model (von Boehmer, 1990 ) however demonstrates that introduction of a switchable c-MycER TM protein into an H-Y-TCR background has in fact an eect on positive thymocyte selection. c-MycER TM activation enhances the eciency of generation of CD8 + SP mature thymocytes. The enhancement of positive selection is probably due to the capacity of cmyc to increase proliferation in these mice in vivo, without causing a concomitant increase in apoptosis. Consistent with this, we were unable to detect any dierence in the level of apoptosis in vivo. However, since apoptotic cells in vivo are rapidly removed, we cannot completely exclude a slight increase in apoptosis as a result of Myc activation. The enhanced eciency of positive selection caused by c-Myc activation might have an impact on the development of clonal thymic tumors observed in c-myc transgenic mice. In Thy1-and CD2-c-myc transgenic mice, thymic tumours that arise exhibit predominantly a double positive phenotype (Spanopoulou et al., 1989; Stewart et al., 1993) suggesting that the sensitivity to c-myc transformation may be restricted to a certain window during their development of T cells.
The in¯uence of c-Myc activation on negative selection is intriguing, but far more dicult to interpret, especially because Myc activation leads to an increase in the CD4 7 CD8 low population and not in the CD4
7 CD8 high population as expected, if c-myc would impair negative selection. The CD4 7 CD8 low thymocytes might be cells that are undergoing apoptosis or cells that are escaping negative selection by downregulating CD8 (Robey et al., 1992) . In line with the second hypothesis, it has been shown that the majority of T cells spared by the deletion due to negative selection express a low density of CD8 molecules (CD8 low ) (Teh et al., 1989; Kisielow et al., 1988) . Our data show that c-Myc activation increases the proportion of CD8 low cells, which means the proportion of cells that are probably escaping negative selection. In the periphery however just a minor increase in CD4 7 CD8 low cells was observed in response to c-Myc activation. These CD4 7 CD8 low cells from male mice are non-functional and unresponsive to H-Y-antigen (Teh et al., 1989) . Therefore the only thing for sure to conclude from our data is that c-myc activation does not seem to enhance negative selection.
As mentioned above, we were unable to detect any dierence in the level of apoptosis in vivo. In vitro, however it has been shown that enforced c-myc expression in growth factor deprived ®broblasts promotes cell cycle progression and triggers apoptosis . Consistent with the reported role for c-Myc in inducing apoptosis, thymocytes from lckc-mycER TM transgenic mice show signi®cant increases in apoptosis above background in vitro compared to thymocytes from wild-type control littermates. Compared to the in vivo situation, in culture thymocytes are displaced from their supporting matrix, they are deprived of any in vivo associations with extracellular matrix or neighbouring thymocytes and trophic signals are not available. Therefore c-Myc-induced apoptosis in the intact thymus is most probably suppressed. The situation seems to be similar in involucrin-c-mycER TM transgenic mice. In these mice c-Myc is also highly eective in inducing apoptosis in keratinocytes in vitro.
In contrast, no appreciable apoptosis is evident upon activation in intact skin epidermis (Pelengaris et al., 1999) .
Materials and methods
Generation of lck-c-mycER
To generate lck-c-mycER TM transgenic mice, a cDNA encoding human c-myc fused to the modi®ed ligand-binding domain of the mouse estrogen receptor (Littlewood et al., 1995) was cloned into the BamHI cloning site of the transgenic expression vector p1070 (Chan et al., 1990) . The puri®ed BamHI fragment containing the lck-c-mycER TM transgene was injected at 10 ng/ml into the male pro nucleus of fertilized C57 C57BL/6/CBA F1 embryos. Resulting embryos were then transferred into day 1-plugged pseudo pregnant foster mice. Transgenic founders were identi®ed by Southern blot analysis of DNA derived from tail snips using a hgh probe to detect the transgenic construct. Heterozygote founder mice were back-crossed to establish founder lines. In this way, two independent lck-c-mycER TM transgenic lines were established. H-Y-TCR transgenic mice (H-2 b/b ) used for breeding were described by (Teh et al., 1988; von Boehmer, 1990 ) and F1 mice arising from lck-c-mycER TM 6H-Y-TCR crosses were used for analysis. The status of the MHC locus in such mice was analysed by Southern blot analysis of tail snip DNA digested with SacI using an H-Y-TCR probe . In all experiments, mice of either H-2 b/k status or of H-2 b/b were compared with each other.
Northern blot analysis
Thymus and spleen tissues were isolated, disaggregated in TRIzol reagent (Gibco ± BRL) by polytron and total RNA was prepared. Twenty mg total RNA was fractionated on a 1% formaldehyde agarose gel and transferred to Hybond N + membrane (Amersham) as described (Sambrook et al., 1989) . Blots were hybridized with a 32 P-labelled human c-myc cDNA as a probe.
Western immunoblot analysis
Tissues were collected and lysed in 125 mM Tris-HCl, pH 8.0, 2 mM EDTA, pH 8.0, 2.5% SDS and 10% b-mercaptoethanol and the total amount of protein determined by Bradford assay (Bio-Rad). Twenty mg protein lysate was fractionated by SDS gel electrophoresis, transferred to a PVDF membrane (Millipore) and probed with monoclonal antibody against human c-myc (9E10) (Evan et al., 1985) . Western immunoblot analysis was performed as described (Evan et al., 1985) and developed using the enhanced chemiluminescence system (Amersham).
In vivo activation of lck-c-mycER TM transgene 4-hydroxytamoxifen (4-OHT) (RBI or Sigma: purity 98% Zisomer) was dissolved in peanut oil (Sigma) at a concentration of 10 mg/ml and aliquots stored at 7208C. The MycER TM protein was activated in vivo by daily intraperitoneal injection of 2 mg 4-hydroxytamoxifen and mice were sacri®ced for analysis after 9 ± 12 administrations. In all experiments control littermates and lck-c-mycER TM transgenic mice were treated in parallel.
Cell surface staining and flow cytometry
Thymuses and lymph nodes were isolated, single cell suspensions prepared and counted using a haemacytometer. 1% BSA/16PBS: anti-CD4-PE, anti-CD8-Avidin, anti-CD8-FITC, anti-CD25-FITC, anti-CD3e-FITC, anti-CD69-FITC, anti-TCR-Avidin, anti-Thy1-Avidin, anti-CD45R-PE, anti-H-Y-TCR-Avidin (a kind gift of Dr Hai-Tao He). Biotinylated antibodies were detected by further staining with streptavidin tricolor (Caltag). Two-and three-colour¯ow cytometry was performed by counting 20 000 events with a FACScan¯ow cytometer (Becton Dickinson) and standard Cell Quest software.
In vivo BrdU labelling
Mice were injected intraperitoneally with 1 mg BrdU (Sigma). Injections were done twice, half an hour apart and the mice sacri®ced 6 h after the second injection. Thymocytes were isolated and stained with an anti-BrdU antibody (Beckton Dickinson) using a standard BrdU labelling protocol (Lucas et al., 1998) .
Purification of splenic T cells
Spleen tissue was isolated and single cell suspensions prepared. Red blood cells were lysed with a Tris-buered ammonium chloride buer and the remaining splenocytes were loaded onto mouse T cell Enrichment Columns (high anity negative selection, R&D systems). Splenic T cells were puri®ed according to the manufacturer's protocol. After puri®cation, cell numbers were determined using a haemacytometer.
In vitro proliferation assays and CFSE staining
To activate the c-mycER TM transgene in vivo lck-c-mycER TM transgenic mice and control littermates were intraperitoneal injected with 4-OHT as described in Materials and methods. Puri®ed splenic T cells from the injected mice were resuspended at a density of 1610 7 cells/ml in 0.1% BSA/ PBS and labelled in vitro with 10 mM carboxy¯uorescein succinimidyl ester (CFSE=CFDA, Molecular Probes) (Wells, 1997; Lyons and Parish, 1994) for 10 min at 378C. Unbound CFSE was quenched by washing twice with cold DMEM medium/10% FCS. Puri®ed CFSE stained splenic T cells were cultured for 72 h in DMEM medium (Gibco ± BRL) supplemented with 10% FCS, 50 mM 2-mercaptoethanol, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 mg/ml streptomycin either in the presence or absence of plate-bound anti-CD3/CD28 antibody (PharMingen: 10 mg/ml each). Anti-CD3 and anti-CD28 antibodies were immobilized by overnight pre incubation at 378C. To keep the Myc protein active during culturing 200 nM 4-OHT was added to the medium and 72 h later cell proliferation was assessed by¯ow cytometry. A control of puri®ed, CFSE stained T cells incubated for the same time without activation helped to identify the population of T cells in the CFSE pro®le that had not yet divided.
Assay of apoptosis by Annexin V staining
Thymus tissue from control littermates and lck-c-mycER TM transgenic mice was isolated and single cell suspensions prepared. 2610 6 thymocytes/6-well were then cultured in DMEM medium (Gibco ± BRL) supplemented with 10% FCS, 5 mM 2-mercaptoethanol, 1 mM pyruvate, 100 U/ml penicillin, 100 mg/ml streptomycin for 18 ± 22 h in the presence or absence of 200 nM 4-OHT and in the presence or absence of Z-VAD-FMK (enzyme systems products). Apoptosis was determined by¯ow cytometry after staining with an anti-Annexin V-FITC antibody (PharMingen).
